Skip to main content

Table 5 Published data on hepatitis C seroprevalence among special unrepresentative populations in Malawi: Published data from 1990 to 2018

From: Epidemiology of hepatitis B, C and D in Malawi: systematic review

Population

Ref

Year

Location

Method

Prevalence (n/total)

Prevalence (%, (95% CI))

Prisoners

[28]

2007

Chichiri Prison, Blantyre

Anti-HCV (Biotec)

0/164

0.0 (0.0, 2.3)

Adult inpatients (Dermatology, Urology)

[32]

1996

KCH, Lilongwe

Anti-HCV EIA (Roche) Confirmed with Anti-HCV (Abbott)

13/333

3.9 (2.3, 6.6)

Adult medical inpatients

[27]

2004

Medical ward, QECH, Blantyre

HCV Ag/Ab (Monolisa, Biorad) confirmed with Immunoassay (Innogenetics)

9/202

4.5 (2.4, 8.2)

Malawian women and children with childhood malignancies

[34]

2006–10

QECH, Blantyre

HBV ELISA (MP Biomedicals)

Mothers: 2/418

0.5 (0.1, 1.7)

Confirmed by HCV BLOT (MP Biomedicals)

Children: 1/418

0.2 (0.0, 1.3)

  1. Abbreviations: Biotec: Dorset, United Kingdom; Roche: Basel, Switzerland; Abbott: Illinois, USA; Innogenetics: Ghent, Belgium; MP Biomedicals: California, USAKCH Kamuzu Central Hospital, QECH Queen Elizabeth Central Hospital, HCV hepatitis C virus